Vertex Pharmaceuticals, a biotech giant best known for its cystic fibrosis drugs, took a stumble after missing Q1 2025 ...

The stock's fall snapped a four-day winning streak.

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

Gulf South Angels, a New Orleans-based investment network, is investing in non-opioid pain drug startup South Rampart Pharma, ...

Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

Vertex Pharmaceuticals VRTX +1.22% Get Free Report has outperformed the market over the past 20 years by 10.58% on an ...

This was the stock's fourth consecutive day of gains.

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics ...

Vertex Pharmaceuticals just pulled out the big guns with a new $4 billion stock repurchase plan, cleverly named the "2025 ...

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian ...

Kidney Health for All is supported by Presenting Sponsors Boehringer Ingelheim and Lilly and Company and Vertex Pharmaceuticals, Inc. and Equity Sponsors AstraZeneca, Merck and Co., Otsuka America ...